非布司他的临床应用和研究进展  

Clinical application and research progress of febuxostat

作　　者：唐颖 余惠凡 郭志磊 Tang Ying;Yu Huifan;Guo Zhilei(Hunan Prevention and Treatment Institute for Occupational Diseases,Changsha 410007,China;Hubei University of Medicine,Shiyan 442000,China;Department of Pharmacy,Wuhan Fourth Hospital,Wuhan 430033,China)

机构地区：[1]湖南省职业病防治院,湖南长沙410007 [2]湖北医药学院,湖北十堰442000 [3]武汉市第四医院药学部,湖北武汉430033

出　　处：《实用药物与临床》2024年第10期790-795,共6页Practical Pharmacy and Clinical Remedies

摘　　要：非布司他作为一种新型降尿酸药物,广泛应用于痛风患者高尿酸血症的长期治疗。此外,非布司他在慢性肾脏疾病、肿瘤溶解综合征以及内皮功能障碍等治疗领域也展现出潜在的临床效益。近年来,随着研究的不断深入,非布司他的心血管安全问题备受关注。本文将对非布司他的临床应用、最新的治疗领域以及心血管安全性进行综述,旨在为临床应用非布司他提供全面指导,并为未来研究方向提供依据。As a new drug for reducing uric acid,febuxostat is widely used in the long-term treatment of hyperuricemia in gout patients.In addition,febuxostat also shows potential clinical benefits in the treatment of chronic kidney disease,tumor lysis syndrome and endothelial dysfunction.In recent years,with the deepening of research,the cardiovascular safety of febuxostat has attracted much attention.This article will review the clinical application,cardiovascular safety and the latest treatment fields of febuxostat,aiming at providing clinicians with comprehensive guidance on the use of febuxostat and providing evidence for future research directions.

关 键 词：非布司他 痛风 临床应用 研究进展 心血管安全性 

分 类 号：R977[医药卫生—药品]